Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

Summary

The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2 diabetes mellitus.

Timeline

Start

2022-10-19

Primary completion

2024-08-20

Completion

2024-09-03

Outcome

Missed primary endpoint

paper the effect on UACR at week 16 was not significantly different from placebo. PMID 41866124 ↗

Publications

• Cherney DZI, Bonefeld K, Crater G, Dwyer JP, Frenkel O, Furberg JF, Knop FK, Kunos G, Lalonde K, Wheeler DC, Wanner C; trial investigators. A double-blind, randomized, placebo-controlled, phase 2 trial examined the efficacy and safety of monlunabant in adults with diabetic kidney disease. Kidney Int. 2026 Jun;109(6):1296-1307. doi: 10.1016/j.kint.2026.02.023. Epub 2026 Mar 20.

Drugs

Indications